GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program. In addition, the company has a collaborative development agreement with The National Institute of Neurological Disorders and Strokes for the development of an antibody program to block the activity of pHERV-K Env; and FondaMental Foundation for the development of diagnostic and therapeutic options for patients with Post-COVID neuropsychiatric syndromes, as well as research collaboration agreement with Northwestern University to confirm evidence of the expression of human endogenous retrovirus W envelope protein (W-ENV or W-ENV) in long-haul COVID patients; and US National Institute of Health for developing new approaches against pHERV-K (K-ENV) protein as a target in the treatment of amyotrophic lateral sclerosis. GeNeuro SA was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Research context
GeNeuro SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
GeNeuro SA is currently in a long term uptrend where the price is trading 11.7% above its 200 day moving average.
From a valuation standpoint, the stock is 40.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 382.8.
Based on the above factors, GeNeuro SA gets an overall score of 1/5.